动员CARs:门诊CART细胞治疗的好处,缺点和方向

Jennifer S Woo1, Kim Nguyen1, Lawrence Liu2

  • 1City of Hope Lennar Foundation Cancer Center, City of Hope National Medical Center, Irvine, CA.

Seminars in hematology
|September 26, 2024
PubMed
概括

化学抗原受体T细胞 (CAR-T) 治疗正在扩展到血液性恶性瘤的门诊机构. 成功实施需要仔细管理潜在的并发症,如细胞因子释放综合征和神经毒性.